Clinical Trials
4 trialsNCT01032070 2024-12-12
PETEY
Astellas Pharma Inc
Phase 2 Terminated
NCT01247922 2024-12-06
Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205
Astellas Pharma Inc
Phase 2 Terminated
NCT00360854 2013-09-20
Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma
National Cancer Institute (NCI)
Phase 1 Unknown
NCT00077454 2013-06-05
Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed